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a b s t r a c t
Objectives: Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) were responsible for 43.3% (235 123/
543 243) and 24.8% (134 607/543 243) of all laboratory-conﬁrmed hand, foot and mouth disease (HFMD)
cases during 2010e2015 in China. Three monovalent EV71 vaccines have been licensed in China while
bivalent EV71/CA16 vaccines are under development. A comparative cost-effectiveness analysis of
bivalent EV71/CA16 versus monovalent EV71 vaccination would be useful for informing the additional
value of bivalent HFMD vaccines in China.
Methods: We used a static model parameterized with the national HFMD surveillance data during 2010
e2013, virological HFMD surveillance records from all 31 provinces in mainland China during 2010e2013
and caregiver survey data of costs and health quality of life during 2012e2013. We estimated the
threshold vaccine cost (TVC), deﬁned as the maximum additional cost that could be paid for a cost-
effective bivalent EV71/CA16 vaccine over a monovalent EV71 vaccine, as the outcome. The base case
analysis was performed from a societal perspective. Several sensitivity analyses were conducted by
varying assumptions governing HFMD risk, costs, discounting and vaccine efﬁcacy.
Results: In the base case, choosing the bivalent EV71/CA16 over monovalent EV71 vaccination would be
cost-effective only if the additional cost of the bivalent EV71/CA16 compared with the monovalent EV71
vaccine is less than V4.7 (95% CI 4.2e5.2). Compared with the TVC in the base case, TVC increased by up
to V8.9 if all the test-negative cases were CA16-HFMD; decreased by V1.1 with an annual discount rate of
6% and exclusion of the productivity loss; and increased by V0.14 and V0.3 with every 1% increase in
bivalent vaccine efﬁcacy against CA16-HFMD and differential vaccine efﬁcacy against EV71-HFMD,
respectively.
Conclusions: Bivalent EV71/CA16 vaccines can be cost-effective compared with monovalent EV71 vac-
cines, if suitably priced. Our study provides further evidence for determining the optimal use of HFMD
vaccines in routine paediatric vaccination programme in China. D. Liu, Clin Microbiol Infect 2019;▪:1
© 2019 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology
and Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Hand, foot and mouth disease (HFMD), commonly affecting
children under 5 years old, has been a serious threat to public
health across Asia over the last two decades [1]. In China, HFMD has
been a notiﬁable disease since May 2008 [2]. The national HFMD
surveillance system registered about 12 million HFMD cases and
2843 deaths during 2010e2015 [3]. Among all the laboratory-
conﬁrmed HFMD cases in 2010e2015, enterovirus 71 (EV71) and
coxsackievirus A16 (CA16) accounted for 39.8% (194 445/488 231)
and 26.9% (131 481/488 231) of mild cases; 73.3% (38 858/53 011)
and 5.8% (3087/53 011) of severe cases; and 92.5% (1850/2001) and
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1.9% (39/2001) of fatal cases, respectively [3]. As no speciﬁc treat-
ment is available for HFMD at present, vaccination is the most
promising intervention to prevent and control epidemics of HFMD
[4].
Three monovalent EV71 vaccines have been licensed in China
since December 2015 and are now commercially available in the
China market [5,6]. Our previous work showed that routine pae-
diatric vaccination with these monovalent EV71 vaccines are likely
to be cost-effective if the cost for vaccinating per child is below
V16.4e17.8 (the variation in cost is driven by differential vaccine
efﬁcacy estimates among the three vaccines) [7]. As of May 2019,
monovalent EV71 vaccines have not yet been included in the
routine paediatric vaccination programme in China, meaning that
they are needed to be paid out-of-pocket by parents (the vaccines
currently cost V21.7e24.3 per dose for two doses per child [8]). As
such, vaccine coverage of these monovalent EV71 vaccines among
children aged 6 months to 5 years ranges from <10% to 50% in
different provinces [9]. Meanwhile, bivalent EV71/CA16 vaccines
are under development and have been shown to induce potent
protective immunity against both EV71 and CA16 in mice [10e12].
These bivalent vaccines have the potential to further reduce the
health burden attributable to HFMD, though the resulting marginal
reduction in severe and fatal cases might not be substantial
compared to monovalent EV71 vaccines because CA16 accounts for
a relatively small percentage of fatal and severe HFMD cases. Our
objective in this study is to characterize the marginal cost and
beneﬁt of bivalent vaccines by comparing the cost-effectiveness of
bivalent EV71/CA16 vaccination and monovalent EV71 vaccination.
Methods
Model
We adapted a previous model that we constructed to estimate
the cost-effectiveness of routine paediatric vaccination using
monovalent EV71 vaccines [7], which was parameterized with
national HFMD surveillance data in 2010e2013 [13], virological
surveillance records from all 31 provinces in mainland China in
2010e2013 [7], and caregiver survey data about costs and health-
related quality of life of lab-conﬁrmed HFMD patients in
2012e2013 [14]. In this new analysis, we assumed that children
were vaccinated at 6 months old with vaccine coverage c and
vaccine protection to at least 5 years old under one of two possible
vaccination programs of (1) a bivalent EV71/CA16 vaccine with
constant vaccine efﬁcacy VE1 against EV71-related HFMD (EV71-
HFMD) and VE2 against CA16-related HFMD (CA16-HFMD); (2) a
monovalent EV71 vaccine with constant vaccine efﬁcacy VEm
against EV71-HFMD (Fig. 1; Tables S1 and S2). Moreover, we
assumed that there was no cross-protection between the two vi-
ruses (Fig. S1) [15,16]. We only considered children aged 6 months
to 5 years old because 90% (10 741 149/11 933 033), 94% (102 672/
108 738) and 96% (2724/2843) of mild, severe and fatal HFMD cases
registered in 2010e2015 occurred in this age group [3,7,13], which
is also the age group currently recommended for monovalent EV71
vaccination [17].
Disease burden
The methodology used to estimate disease burden of EV71-
HFMD and CA16-HFMD (written as EV71/CA16-HFMD hereafter)
was conceptually the same as that in our previous study [7].
Following the methodology in our previous paper, to account for
the uncertainty regarding the percentages of test-negatives that
were EV71/CA16-HFMD in the national surveillance data, we used
virological surveillance records from all 31 provinces to
supplement national surveillance data and considered 51 scenarios
(Fig. S2) (please see supplementary material, Uncertainty regarding
test-negatives, for details).
We assumed that in the absence of vaccination, the long-term
average risk of mild, severe and fatal EV71/CA16-HFMD in future
birth cohorts would be identical to that registered by the national
surveillance system between 2010 and 2013. The national average
risk of mild, severe and fatal serotype-speciﬁc HFMD were esti-
mated as the sum of the number of that disease in all 31 provinces
in 2010e2013 divided by the total number of new births during the
same years (Table 1).
Vaccine efﬁcacy
Ameta-analysis using a random-effect model showed an overall
1-year efﬁcacy of monovalent EV71 vaccines of 95% (90e98%)
[18e21]. As such, we assumed that VEm, VE1 and VE2 were all 95% in
the base case scenario. For sensitivity analysis, we assumed that
both VE1 and VE2 varied between 70% and 100%, i.e. the differential
vaccine efﬁcacy against EV71 between the two vaccines, DVE1 ¼
VE1  VEm, varied between e25% and 5%.
Costs, QALY loss and cost-effectiveness
We estimated costs and quality-adjusted life-year (QALY) loss
per birth due to EV71/CA16-HFMD using the same methodology as
in our previous paper (please see supplementary material, Costs
and QALY loss) [7]. We calculated the threshold vaccine cost (TVC)
for bivalent EV71/CA16 vaccine compared to monovalent EV71
vaccine as the outcome in our analysis. TVC was deﬁned as the
maximum additional cost that could be paid for a cost-effective
bivalent EV71/CA16 vaccine compared to the monovalent EV71
vaccine. Given a particular societal willingness-to-pay (WTP)
threshold, the TVC was calculated as follows:
TVC ¼ DVE1  ðWTP threshold  Q1 þ C1Þ þ VE2
 ðWTP threshold  Q2 þ C2Þ (1)
where C1 and Q1 denoted the costs and QALY loss due to EV71-
HFMD per birth, and C2 and Q2 denoted the costs and QALY loss
due to CA16-HFMD per birth [14]. Choosing the bivalent EV71/CA16
vaccine over the monovalent EV71 vaccine would be cost-effective
only if the bivalent vaccine cost was no more than TVC extra
compared to that of the monovalent vaccine. In the base case
analysis, as VE1 was assumed to be equal to VEm (i.e. DE1 ¼ 0), TVC
here was just VE2  (WTP threshold  Q2 þ C2) (please see sup-
plementary material, Threshold vaccine cost (TVC), for details).
In the base case, a WTP threshold of one gross domestic product
per capita (GDPpc; V7698 in 2017) was applied because it is
commonly used in China [22,23]. A societal perspective was used
(including parent/caregiver out-of-pocket costs and productivity
losses), and costs and health utilities were discounted at a rate of 3%
per annum. All costs were reported in Chinese Yuan during
2012e2013 but were inﬂated to 2017e2018 prices using China's
annual consumer price index (healthcare) [24], before being con-
verted to 2017 Euro (1 euro ¼ 7.75 Chinese Yuan).
Uncertainty analysis
Scenario sensitivity analyses were conducted by varying as-
sumptions governing HFMD risk, costs, discounting and vaccine
efﬁcacies, as follows: (1) the estimated risk of EV71/CA16-HFMD
in the 51 scenarios generated by the three assumptions
mentioned above; (2) inclusion or exclusion of productivity loss of
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parents/caregivers in estimating costs; (3) discount rate at 3% or
6% per annum; (4) variation in DVE1 and VE2 as mentioned above.
In addition, we conducted probabilistic sensitivity analysis by
varying HFMD risk, costs and QALY loss due to EV71/CA16-HFMD
across the 51 test-negative scenarios described above. See Table 1
for details.
Results
Base case analysis
In the base case analysis, choosing a bivalent EV71/CA16 vaccine
over a monovalent EV71 vaccine would be cost-effective only if the
Mild EV71-HFMD, mild CA16-HFMD
Mild EV71-HFMD, severe CA16-HFMD
Mild EV71-HFMD, fatal CA16-HFMD
Severe EV71-HFMD, mild CA16-HFMD
Severe EV71-HFMD, severe CA16-HFMD
Severe EV71-HFMD, fatal CA16-HFMD
Fatal EV71-HFMD, mild CA16-HFMD
Fatal EV71-HFMD, severe CA16-HFMD
Fatal EV71-HFMD, fatal CA16-HFMD
Mild EV71-HFMD, no CA16-HFMD
Severe EV71-HFMD, no CA16-HFMD
Fatal EV71-HFMD, no CA16-HFMD
Mild CA16-HFMD, no EV71-HFMD
Severe CA16-HFMD, no EV71-HFMD
Fatal CA16-HFMD, no EV71-HFMD
No EV71/CA16-HFMD
No Vaccination
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No Vaccination
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c
c
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[(1 - ε1) Pm1] * [(1 - ε2) Pf2]
[(1 - ε1) Ps1] * [(1 - ε2) Pm2]
[(1 - ε1) Ps1] * [(1 - ε2) Ps2]
[(1 - ε1) Ps1] * [(1 - ε2) Pf2]
[(1 - ε1) Pf1] * [(1 - ε2) Pm2]
[(1 - ε1) Pf1] * [(1 - ε2) Ps2]
[(1 - ε1) Pf1] * [(1 - ε2) Pf2]
[(1 - ε1) Pm1] * [1 - (1 - ε2) P2]
[(1 - ε1) Ps1] * [1 - (1 - ε2) P2]
[(1 - ε1) Pf1] * [1 - (1 - ε2) P2]
[1 - (1 - ε1) P1] * [(1 - ε2) Pm2]
[1 - (1 - ε1) P1] * [(1 - ε2) Ps2]
[1 - (1 - ε1) P1] * [(1 - ε2) Pf2]
[1 - (1 - ε1) P1] * [1 - (1 - ε2) P2]
(A)
(B)
Fig. 1. Model structure. A birth cohort was assumed to be vaccinated by one of the two vaccination strategies: (A) bivalent EV71/CA16 vaccination with a vaccine coverage c and
vaccine efﬁcacy VE1 against EV71-HFMD and VE2 against CA16-HFMD; (B) monovalent EV71 vaccination with a vaccine coverage c and vaccine efﬁcacy VEm against EV71-HFMD. The
timeframe was assumed to be 6 months to 5 years old. The ellipses indicated the same outcomes as bivalent EV71/CA16 vaccination. Pm1, Ps1 and Pf1 denote the national average risk
of mild, severe and fatal EV71-HFMD per birth; Pm2, Ps2 and Pf2 denote the national average risk of mild, severe and fatal CA16-HFMD per birth; P1 and P2 denote the national average
risk of EV71-HFMD and CA16-HFMD per birth; ε1 and ε2 denote the proportion of EV71-HFMD and CA16-HFMD prevented by each vaccination strategy, respectively. Therefore, ε1
and ε2 are (1) respectively equal to VE1 and VE2 under bivalent EV71/CA16 vaccination; (2) respectively equal to VEm and 0 under monovalent EV71 vaccination; (3) both equal to
0 under no vaccination (see Tables S1 and S2 for detailed outcome probabilities). HFMD, hand, foot and mouth disease.
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cost of the bivalent vaccine was no more than V4.7 (95% CI
V4.2e5.2) higher than that of the monovalent EV71 vaccine.
Moreover, bivalent EV71/CA16 vaccination would be cost-effective
compared to no vaccination if the total costs of bivalent EV71/
CA16 vaccination per birth were no more than V22.0 (21.1e23.0).
The number of mild CA16-HFMD cases was 300 and 30 000
times higher than that of severe and fatal cases (Fig. 2A). Conse-
quently, the risk of mild CA16-HFMD cases was the most important
driving factor of the TVC (Fig. 3) even though the costs and QALY
loss per episode due to severe and fatal CA16-HFMD were higher
than those of mild CA16-HFMD. The costs and QALY loss attribut-
able to mild CA16-HFMD were the main constituents of the TVC,
accounting for 80% (V3.77/V4.7) and 13% (V0.61/V4.7), respec-
tively (Fig. 2B and C).
Uncertainty analysis
Compared to the base case scenario (scenario 1), the TVC
increased by (1) 46e87% (V2.2e4.1/V4.7) if the percentage of mild
test-negatives that were EV71/CA16-HFMD was the same as that of
Table 1
Model parameters and their sources
Base case Uncertainty analysis Distribution Source
Lifetime risk (per 100 000 births)
EV71-Mild 3088 2932e7077a Dirichlet distribution National HFMD surveillance data and
virological surveillance records from all
31 provinces in mainland China
between 2010 and 2013 [7,13]
EV71-Severe 83.4 75e107a
EV71-Fatal 3.13 3.04e3.53a
CA16-Mild 2,162 2083e6228a
CA16-Severe 6.6 5.8e37.3a
CA16-Fatal 0.07 0.07e0.54a
Costs (per case, excluding productivity loss, V)
EV71-Mild 693.8 Bivariate normal distribution Caregiver survey data about costs and
health-related quality of life of lab-
conﬁrmed HFMD patients between
2012 and 2013 [14]
EV71-Severe 2851.8
EV71-Fatal 2392.8
CA16-Mild 360.6
CA16-Severe 2433.7
CA16-Fatal 2264.4
Costs (per case, including productivity loss, V)
EV71-Mild 761.0 Bivariate normal distribution Caregiver survey data about costs and
health-related quality of life of lab-
conﬁrmed HFMD patients between
2012 and 2013 [14]
EV71-Severe 2970.8
EV71-Fatal 2567.3
CA16-Mild 419.4
CA16-Severe 2552.5
CA16-Fatal 2422.4
Costs (per birth, excluding productivity loss, V)
EV71-Mild 5.73 Bivariate normal distribution Caregiver survey data about costs and
health-related quality of life of lab-
conﬁrmed HFMD patients between
2012 and 2013 [14]
EV71-Severe 2.41
EV71-Fatal 0.06
CA16-Mild 3.02
CA16-Severe 0.16
CA16-Fatal 0.001
Costs (per birth, including productivity loss, V)
EV71-Mild 7.37 Bivariate normal distribution Caregiver survey data about costs and
health-related quality of life of lab-
conﬁrmed HFMD patients between
2012 and 2013 [14]
EV71-Severe 2.52
EV71-Fatal 0.07
CA16-Mild 3.97
CA16-Severe 0.17
CA16-Fatal 0.001
QALY loss (per case)
EV71-Mild 0.006 Bivariate normal distribution Caregiver survey data about costs and
health-related quality of life of lab-
conﬁrmed HFMD patients between
2012 and 2013 [14]
EV71-Severe 0.01
EV71-Fatal 30.4
CA16-Mild 0.005
CA16-Severe 0.01
CA16-Fatal 30.4
QALY loss (per 10 000 births)
EV71-Mild 1.12 e Bivariate normal distribution Caregiver survey data about costs and
health-related quality of life of lab-
conﬁrmed HFMD patients between
2012 and 2013 [14]
EV71-Severe 0.12 e
EV71-Fatal 9.53 e
CA16-Mild 0.83 e
CA16-Severe 0.01 e
CA16-Fatal 0.23 e
Vaccine efﬁcacy
VE1 95% 70e100% Uniform distribution Assumed
VE2 95% 70e100% Uniform distribution Assumed
VEm 95% e Vaccine efﬁcacy reported in phase III
trials of three monovalent EV71
vaccines [19e21]
DVE1 (¼VE1 e VEm) 0% e25e5% Uniform distribution Assumed
Discount rate per annum 3% 3% or 6% Assumed
Willingness-to-pay threshold one GDPpc e Assumed
GDPpc, gross domestic product per capita; HFMD, hand, foot and mouth disease; QALY, quality-adjusted life-year.
a Values for uncertainty analysis were the estimating risk of EV71-HFMD and CA16-HFMD in all the 51 scenarios in Fig. S2.
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Fig. 2. Estimated risk, costs, and QALY loss attributable to CA16-HFMD in the base case. In the base case, both vaccines are equally efﬁcacious against EV71-HFMD. The error bars
show the 95% CIs. (A) The estimated national average risk of CA16-HFMD per 100 000 births. (B) Estimated costs and QALY loss due to CA16-HFMD per birth. Costs were inﬂated to
2017e18 prices before being converted to Euro. The estimated costs due to mild, severe and fatal CA16-HFMD per birth were V3.97 (3.50e4.43), V0.17 (0.13e0.22) and V0.001
(0.001-0.002), respectively. The estimated QALY loss (times WTP threshold) due to mild, severe and fatal CA16-HFMD per birth were V0.63 (0.49e0.78), V0.006 (0.004e0.007) and
V0.17 (0.17e0.17), respectively. (C) Percentage breakdown of estimated costs and QALY loss due to CA16-HFMD per birth. HFMD, hand, foot and mouth disease; QALY, quality-
adjusted life-year; WTP threshold, willingness-to-pay threshold, deﬁned as one gross domestic product per capita (V7698 in 2017) in the base case.
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mild test-positives (scenarios of the 2nd column in Fig. S2); (2)
66e107% (V3.1e5.0/V4.7) if all the mild test-negatives were EV71/
CA16-HFMD (scenarios of the 4th column in Fig. S2); 3) 147e190%
(V6.9e8.9/V4.7) if all the mild test-negatives were CA16-HFMD
(scenarios of the 5th column in Fig. S2). Compared to TVC with
an annual discount rate of 3% and the inclusion of productivity
losses in the cost estimate, TVC decreased by (1) 5.3% (V0.65/V12.3)
e 11.5% (V0.78/V6.8) if the annual discount rate was 6%; (2) 14.7%
(V1.00/V6.8) e 20.5% (V2.39/V11.6) if productivity losses were
excluded; (3) 24.4% (V3.14/V12.9) e 25.6% (V1.56/V6.1) if the
annual discount rate was 6% and productivity losses were excluded
(Table S3).
Generally, TVC increased by ðWTP threshold 
Q1 þ C1Þ = 100 and ðWTP threshold  Q2 þ C2Þ = 100 with every
1% increase in DVE1 and VE2, respectively. Hence, TVC increased
monotonically with DVE1 and VE2, and was more sensitive to DVE1
than VE2. By ﬁxing other parameters to their base case values, TVC
increased by (1) V0.18eV0.30 for every 1% increase in DVE1 among
all the 51 scenarios; (2) V0.05eV0.14 for every 1% increase in VE2
among all the 51 scenarios (Fig. S3).
Additionally, we have built an online app to enable the readers
to explore all the possible TVC results corresponding to different
assumptions governing HFMD risk, costs, discounting and vaccine
efﬁcacies (https://diliu-hku.shinyapps.io/shinyapp_cea_hfmd/).
Discussion
Our study is the ﬁrst to compare the cost-effectiveness of a
bivalent EV71/CA16 vaccine to that of a monovalent EV71 vaccine
for reducing the burden of HFMD in China. In the base case analysis,
our results suggest that choosing bivalent EV71/CA16 vaccination
over monovalent EV71 vaccination could be cost-effective if the
cost of bivalent EV71/CA16 vaccination per birth was no more than
V4.7 (95% CIV4.2e5.2) above that of monovalent EV71 vaccination.
Our results show that in the base case, bivalent EV71/CA16
vaccine could prevent 70% (2162/3088), 8% (6.6/83.4) and 2% (0.07/
3.13) more mild, severe and fatal cases than monovalent EV71
vaccine by preventing CA16-HFMD cases. This is in line with our
results indicating that the risk of mild CA16-HFMD is the most
important determinant of the comparative cost-effectiveness of
bivalent EV71/CA16 vaccine versus monovalent EV71 vaccine.
Therefore, an apparent change in risk of mild CA16-HFMD cases
might affect the comparative cost-effectiveness of bivalent EV71/
CA16 vaccines versus monovalent EV71 vaccines. However, about
33% (162 305/488 231) of mild HFMD cases in Chinawere caused by
other enteroviruses in 2010e2015 [3] and the incidence of mild
HFMD cases attributable to other enteroviruses, especially CA6, has
been increasing in recent years [25e27]. As such, the TVC under
which the bivalent EV71/CA16 vaccine would be cost-effective
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Fig. 3. Comparative cost-effectiveness of routine paediatric bivalent EV71/CA16 versus monovalent EV71 vaccination. TVC was calculated with a societal willingness-to-pay
threshold of one GDPpc, an annual discount rate of 3% and VEm ¼ VE1 ¼ VE2 ¼ 95%. (A) TVC (V) of the 51 scenarios regarding HFMD risk from Fig. S2 are listed along the x-
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correspond to higher percentage. The red arrow indicates the base case (scenario 1). (BeD) The risk of mild, severe, and fatal CA16-HFMD listed along the x-axis in ascending order
of TVC. The error bars show the 95% CIs, but in some cases they are not apparent for the risk of mild and severe CA16-HFMD. Fig. 3A and B have a similar trend, indicating that the
TVC depends mainly on the risk of mild CA16-HFMD. The percentage of mild test-negatives that were CA16-HFMD (top row of the square grids) also has a similar trend to Fig. 3A.
HFMD, hand, foot and mouth disease.
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compared with monovalent EV71 vaccine may vary signiﬁcantly
with the changing aetiology of HFMD in China.
Given that bivalent EV71/CA16 vaccines are still undergoing
clinical trials, their vaccine efﬁcacies remain unknown. Nonethe-
less, our results will be useful to vaccine manufacturers for un-
derstanding themarket value and potential return on investment of
a bivalent vaccine, as well as the way it depends not only on its
vaccine efﬁcacy but also those of the monovalent EV71 vaccines.
They are also useful to purchasers (e.g. China's National Health
Commission) when a vaccine eventually becomes available. Our
results demonstrate that TVC is more sensitive to the differential
vaccine efﬁcacy against EV71 (DVE1) than the vaccine efﬁcacy
against CA16 (VE2). If the current bivalent vaccine is successful in
clinical trials and licensure, the reported efﬁcacy ﬁgures can be
used to generate more precise estimates.
Our study has several limitations [7]. First, we have likely
underestimated the economic and health burden of EV71/CA16-
HFMD (and potentially cost-effectiveness of a bivalent vaccine)
because not all HFMD cases have been registered in the national
surveillance data. Second,we assumed that the long-term incidence
of EV71/CA16-HFMD in the futurewould be similar to that estimated
from national surveillance data between 2010 and 2013, whereas
the aetiology of HFMD in China may signiﬁcantly change over time.
Third, we did not account for adverse events of vaccination and
productivity losses due to premature death, which respectively
could decrease and increase the TVC. Fourth, we assumed that the
vaccine protection is at least 5 years for both the monovalent and
bivalent vaccines. If the bivalent EV71/CA16 vaccine efﬁcacies or
monovalent EV71 vaccine efﬁcacy or both wane within the 5-year
time period, the TVC would also change. Wei et al. reported
similar 2-year vaccine efﬁcacy to 1-year vaccine efﬁcacy of Vigoo
monovalent EV71 vaccine against EV71-HFMD [21,28]. While there
are no data about the vaccine efﬁcacy of bivalent vaccines, their
results provide partial support for our assumption that bivalent
vaccine efﬁcacy does not decrease greatlywithin 5 years. Finally, we
assumed that there is no cross-protection among EV71, CA16 and
other enteroviruses. Although Takahashi et al. reported that EV71
and CA16might provide around 7weeks of cross-protection against
each other, the results from Pons-Salort and Grassly implied that
such level of cross-protection is sufﬁciently low such that the
epidemic dynamics of thedifferentHFMDserotypes canbe regarded
as independent of each other [15,16].
Studies have shown that a national introduction of highly
effective bivalent EV71/CA16 vaccines would have the potential to
greatly reduce the incidence of EV71/CA16-HFMD in the long run.
Takahashi et al. [15] simulated the 10-year effect following intro-
duction of a 100% effective bivalent EV71/CA16 vaccine nationwide
in China and found that a vaccine coverage of 90% led to almost no
EV71/CA16-HFMD cases from 6 years after its introduction. Simi-
larly, Pons-Salort and Grassly simulated the effect of introducing a
100% effective bivalent EV71/CA16 vaccine in Japan, and showed
that a similar coverage led to almost no EV71/CA16-HFMD cases
from 2 years after its introduction [16].
The Chinese national routine paediatric vaccination programme
was last expanded in 2007 when measles, mumps and rubella
vaccine, epidemic encephalitis vaccine, meningococcal meningitis
vaccine and hepatitis A vaccine were added to the programme
(with the oral polio vaccine replaced by inactivated polio vaccine in
2016) [29]. Since then, China has increased its GDPpc substantially
from V2646 to V7698 and hence has the ﬁnancial resources to
expand its national vaccination programme to improve population
health as well as productivity. Given that HFMD is the most prev-
alent notiﬁable infectious disease in China for children under
5 years, HFMD vaccines should be amongst the top candidates for
inclusion into the programme.
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